Cargando…

1143. Meningococcal Vaccination Coverage Disparities in the United States: An Analysis with 2016-2021 National Immunization Survey-Teen Data

BACKGROUND: The US Advisory Committee on Immunization Practices recommends meningococcal vaccination against serogroups A, C, W, and Y (MenACWY) for 11–12 year-olds (y/o) with a booster at 16; and against serogroup B (MenB) for 16–23 y/o under shared clinical decision making (SCDM). We used a large...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrera-Restrepo, Oscar, Kwiatkowska, Marta, Ndegwa, Nelson, Poston, Sara, Ganz, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677981/
http://dx.doi.org/10.1093/ofid/ofad500.984
_version_ 1785150257799102464
author Herrera-Restrepo, Oscar
Kwiatkowska, Marta
Ndegwa, Nelson
Poston, Sara
Ganz, Michael
author_facet Herrera-Restrepo, Oscar
Kwiatkowska, Marta
Ndegwa, Nelson
Poston, Sara
Ganz, Michael
author_sort Herrera-Restrepo, Oscar
collection PubMed
description BACKGROUND: The US Advisory Committee on Immunization Practices recommends meningococcal vaccination against serogroups A, C, W, and Y (MenACWY) for 11–12 year-olds (y/o) with a booster at 16; and against serogroup B (MenB) for 16–23 y/o under shared clinical decision making (SCDM). We used a large US survey to assess vaccination coverage across vaccines, geography and race/ethnicity. METHODS: This was a cross-sectional analysis using 2016-2021 National Immunization Survey-Teen survey data on MenACWY (≥1 dose [d]) in 13 y/o, MenACWY (≥2 d) and MenB (≥1 d) in 17 y/o. Data were collected via phone interviews with provider confirmation. We assessed coverage throughout the calendar year for MenACWY (≥1 d) and MenB (≥1 d) after the interview date, and for MenACWY (≥2 d) at the interview date. RESULTS: MenACWY coverage (≥1 d) in 13 y/o evolved from 82.71% (2016) to 86.42% (2021). MenACWY coverage (≥1 d) in 13-17 y/o changed from 83.36% (2016) to 89.82% (2021). MenB coverage (≥1 d) in 17 y/o changed from 5.63% (2016) to 34.05% (2021). Geographic coverage was more variable moving from MenACWY (≥1 d) in 13 y/o (74.44% Pacific region 2016 to 91.00% New England region 2021) to MenACWY (≥2 d) in 17 y/o (21.05% East South Central region 2016 to 75.68% Mid-Atlantic region 2021) and MenB (≥1 d) in 17 y/o (2.34% Pacific region 2016 to 45.29% South Atlantic region 2021). MenACWY coverage (≥1 d) in 13 y/o was consistent across race/ethnicity, while 17 y/o Hispanic had lower MenACWY coverage (≥2 d) in 2021 (50.63%). For MenB (≥1 d) in 17 y/o, coverage varied by race/ethnicity; coverage in Hispanic and Non-Hispanic (NH) Black populations increased from 5.55% and 7.55% to 33.58% and 42.33% over 5 years, respectively. In NH White population, coverage yearly increased from 5.29% to 33.88%, while it only progressed from 5.34% to 27.17% in other NH + Multiple race population. CONCLUSION: Meningococcal vaccination disparities persist across vaccines, ages, geography, and race/ethnicity (MenB only). Disparities increase with age, and with SCDM- versus routinely- recommended vaccines (MenB vs. MenACWY). Top performing states show that better coverage is possible (∼70% MenB coverage in North Dakota vs. 34% nationally in 2021), pointing at the need to reduce access barriers to vaccination, e.g., via simplified vaccine recommendations/schedules. DISCLOSURES: Oscar Herrera-Restrepo, PhD, GSK: Stocks/Bonds Sara Poston, PharmD, GSK: Stocks/Bonds
format Online
Article
Text
id pubmed-10677981
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106779812023-11-27 1143. Meningococcal Vaccination Coverage Disparities in the United States: An Analysis with 2016-2021 National Immunization Survey-Teen Data Herrera-Restrepo, Oscar Kwiatkowska, Marta Ndegwa, Nelson Poston, Sara Ganz, Michael Open Forum Infect Dis Abstract BACKGROUND: The US Advisory Committee on Immunization Practices recommends meningococcal vaccination against serogroups A, C, W, and Y (MenACWY) for 11–12 year-olds (y/o) with a booster at 16; and against serogroup B (MenB) for 16–23 y/o under shared clinical decision making (SCDM). We used a large US survey to assess vaccination coverage across vaccines, geography and race/ethnicity. METHODS: This was a cross-sectional analysis using 2016-2021 National Immunization Survey-Teen survey data on MenACWY (≥1 dose [d]) in 13 y/o, MenACWY (≥2 d) and MenB (≥1 d) in 17 y/o. Data were collected via phone interviews with provider confirmation. We assessed coverage throughout the calendar year for MenACWY (≥1 d) and MenB (≥1 d) after the interview date, and for MenACWY (≥2 d) at the interview date. RESULTS: MenACWY coverage (≥1 d) in 13 y/o evolved from 82.71% (2016) to 86.42% (2021). MenACWY coverage (≥1 d) in 13-17 y/o changed from 83.36% (2016) to 89.82% (2021). MenB coverage (≥1 d) in 17 y/o changed from 5.63% (2016) to 34.05% (2021). Geographic coverage was more variable moving from MenACWY (≥1 d) in 13 y/o (74.44% Pacific region 2016 to 91.00% New England region 2021) to MenACWY (≥2 d) in 17 y/o (21.05% East South Central region 2016 to 75.68% Mid-Atlantic region 2021) and MenB (≥1 d) in 17 y/o (2.34% Pacific region 2016 to 45.29% South Atlantic region 2021). MenACWY coverage (≥1 d) in 13 y/o was consistent across race/ethnicity, while 17 y/o Hispanic had lower MenACWY coverage (≥2 d) in 2021 (50.63%). For MenB (≥1 d) in 17 y/o, coverage varied by race/ethnicity; coverage in Hispanic and Non-Hispanic (NH) Black populations increased from 5.55% and 7.55% to 33.58% and 42.33% over 5 years, respectively. In NH White population, coverage yearly increased from 5.29% to 33.88%, while it only progressed from 5.34% to 27.17% in other NH + Multiple race population. CONCLUSION: Meningococcal vaccination disparities persist across vaccines, ages, geography, and race/ethnicity (MenB only). Disparities increase with age, and with SCDM- versus routinely- recommended vaccines (MenB vs. MenACWY). Top performing states show that better coverage is possible (∼70% MenB coverage in North Dakota vs. 34% nationally in 2021), pointing at the need to reduce access barriers to vaccination, e.g., via simplified vaccine recommendations/schedules. DISCLOSURES: Oscar Herrera-Restrepo, PhD, GSK: Stocks/Bonds Sara Poston, PharmD, GSK: Stocks/Bonds Oxford University Press 2023-11-27 /pmc/articles/PMC10677981/ http://dx.doi.org/10.1093/ofid/ofad500.984 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Herrera-Restrepo, Oscar
Kwiatkowska, Marta
Ndegwa, Nelson
Poston, Sara
Ganz, Michael
1143. Meningococcal Vaccination Coverage Disparities in the United States: An Analysis with 2016-2021 National Immunization Survey-Teen Data
title 1143. Meningococcal Vaccination Coverage Disparities in the United States: An Analysis with 2016-2021 National Immunization Survey-Teen Data
title_full 1143. Meningococcal Vaccination Coverage Disparities in the United States: An Analysis with 2016-2021 National Immunization Survey-Teen Data
title_fullStr 1143. Meningococcal Vaccination Coverage Disparities in the United States: An Analysis with 2016-2021 National Immunization Survey-Teen Data
title_full_unstemmed 1143. Meningococcal Vaccination Coverage Disparities in the United States: An Analysis with 2016-2021 National Immunization Survey-Teen Data
title_short 1143. Meningococcal Vaccination Coverage Disparities in the United States: An Analysis with 2016-2021 National Immunization Survey-Teen Data
title_sort 1143. meningococcal vaccination coverage disparities in the united states: an analysis with 2016-2021 national immunization survey-teen data
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677981/
http://dx.doi.org/10.1093/ofid/ofad500.984
work_keys_str_mv AT herrerarestrepooscar 1143meningococcalvaccinationcoveragedisparitiesintheunitedstatesananalysiswith20162021nationalimmunizationsurveyteendata
AT kwiatkowskamarta 1143meningococcalvaccinationcoveragedisparitiesintheunitedstatesananalysiswith20162021nationalimmunizationsurveyteendata
AT ndegwanelson 1143meningococcalvaccinationcoveragedisparitiesintheunitedstatesananalysiswith20162021nationalimmunizationsurveyteendata
AT postonsara 1143meningococcalvaccinationcoveragedisparitiesintheunitedstatesananalysiswith20162021nationalimmunizationsurveyteendata
AT ganzmichael 1143meningococcalvaccinationcoveragedisparitiesintheunitedstatesananalysiswith20162021nationalimmunizationsurveyteendata